(Q34530229)

2 August 2017

1 reference

title

What should the role of ACE inhibitors be in the treatment of diabetes? Lessons from HOPE and MICRO-HOPE. (English)

1 reference

2 August 2017

Robert E Heinig

1

1 reference

2 August 2017

publication date

1 January 2002

1 reference

Diabetes, Obesity and Metabolism

2 August 2017

published in

1 reference

2 August 2017

volume

4 Suppl 1

1 reference

2 August 2017

page(s)

S19-25

1 reference

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00036.X

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00036.X

The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00036.X

Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00036.X

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00036.X

Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00036.X

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00036.X

Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00036.X

Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00036.X

Improved insulin action and glycemic control after long-term angiotensin-converting enzyme inhibition in subjects with arterial hypertension and type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00036.X

Angiotensin-Converting Enzyme Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00036.X

Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. QUIET Investigators. QUinapril Ischemic Event Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00036.X

Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00036.X

Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00036.X

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00036.X

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00036.X

Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00036.X

Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00036.X

10.1046/J.1462-8902.2001.00036.X

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference